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Patients who develop signiﬁcant dysphagia secondary to a potentially curable oesophageal cancer pose a
signiﬁcant clinical problem. Their nutritional needs can be met either by dietary supplementation,
insertion of an oesophageal stent or through nasogastric or surgical feeding tube placement. We sought
to determine whether, in patients about to start neo-adjuvant therapy prior to oesophagectomy, the use
of oesophageal stent improves clinical outcomes. A best evidence topic in upper gastrointestinal surgery
was written according to a structured protocol in order to answer this question. Two hundred and forty
eight papers were found, of which eleven level III and one level IV study were considered to best address
the clinical question. These indicate that whilst oesophageal stents do successfully relieve dysphagia
throughout neoadjuvant therapy, they are not consistently associated with maintenance of, or
improvement in, serum albumin or body weight. They are, however, commonly associated with stent
migration and chest discomfort, both of which may frequently result in the need for stent removal or
replacement. There is additional evidence within the manuscripts reviewed to demonstrate that the use
of oesophageal stents in the neoadjuvant setting can lead to signiﬁcant complications in a small pro-
portion of patients which can compromise opportunity for curative surgery. The use of stents in this
situation cannot be recommended.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Oesophageal malignancy commonly presents with dysphagia
and weight loss. Given that subsequent malnutrition is associated
with poorer outcomes for both neoadjuvant therapy and surgery,
maintaining adequate nutrition during neoadjuvant treatment is
vital [1,2]. Strategies to address nutritional requirements include
dietary supplementation, nasojejunal tube placement and feeding
jejunostomy insertion. Each method has speciﬁc risks and advan-
tages. Oesophageal stents, for example, have the beneﬁt of
permitting enteral nutrition without a visible feeding tube or the
requirement to connect to a feeding pump. However, little is known
about their efﬁcacy or safety. We constructed a best evidencen Elizabeth Hospital, Univer-
Edgbaston, Birmingham B15
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by Elsevier Ltd. All rights reservedsearch according to a structured protocol, as described in a
manuscript published within the International Journal of Surgery
[3]. This BestBET, part of a series designed to answer clinically
relevant questions and allow clinicians to rapidly review the liter-
ature on a deﬁned topic, reviews the use of oesophageal stents in
patients undergoing neoadjuvant therapy prior to planned
oesophagectomy.2. Clinical scenario
You are in the outpatient clinic with a 73 year old man with
oesophageal cancer. Staging investigations, including computer
tomography, endoscopic ultrasound and positron emission to-
mography have shown a surgically resectable T3N1 oesophageal
adenocarcinoma. He has become severely dysphagic and is about to
embark on neo-adjuvant chemotherapy. The patient is worried
about losing weight and asks about the possibility of an oesopha-
geal stent to alleviate his swallowing problems whilst awaiting
potentially curative surgery. You elect to review the literature in.
Table 1
Best evidence papers.
Article & level of
evidence
Patient group assessed Type of stent used Outcomes assessed Summary of ﬁndings Comments
Christie A. 2001.
USA. [4]
Level III: Follow
up study
One hundred patients within a
single tertiary referral centre with
either oesophageal malignancy or
lung cancer (7%) and dysphagia.
Expandable metal
stent. (Ultraﬂex).
Relief of dysphagia Dysphagia relieved up to the time
of oesophagectomy in 14/16
patients (88%). 2/16 (12,5%)
required a feeding tube for
nutritional supplementation.
Only a small subset of patients
had stents to cover neoadjuvant
CT. No comment is made on
change in objective markers of
nutrition, nor on impact on
progression to surgery.Complications Two complications speciﬁc to
those undergoing neoadjuvant
therapy noted; one patient had
stent placed in the proximal
oesophagus and developed stent
erosion into the T1 vertebral body,
requiring subsequent
neurosurgical drainage, whilst
another developed a mediastinal
abscess related to an occult stent
perforation and erosion. This
recurred following
oesophagectomy and the patient
died from sepsis.
Bower M. 2009.
USA. [5]
Level III: Follow
up study.
Twenty ﬁve patients within a
single tertiary referral centre
between January 1998 and July
2008 with oesophageal
malignancy and stricture causing
signiﬁcant dysphagia. All had
undergone neoadjuvant CRT after
stent placement with a view to
subsequent surgical resection.
Self expanding
silicone-covered
stent. (Polyﬂex).
Complications Immediate 1/25 (4%) experienced chest
discomfort, alleviated with oral
analgesics.
No note is made of the proportion
for whom stent insertion was not
a technical success. Stent
placement is compared to 19
patients with feeding tubes placed
and 14 nonstented patients
maintained on oral diet, all of
whom underwent neoadjuvant
therapy.
Early 2/25 (8%) required nasoduodenal
tubes to support nutrition.
Late 6/25 (24%) experienced stent
migration, 5/6 (83.3%) of whom
required removal of the stent.
Change in dysphagia
score
Dysphagia signiﬁcantly improved
from 3.5/4 to 1.3/4 (p < 0.001)
Change in serum albumin Mean serum albumin signiﬁcantly
improved by 0.14 g/dL (p < 0.001)
over the course of neoadjuvant
CRT.
Change in body weight No signiﬁcant change in body
weight over the course of
neoadjuvant CRT.
Progression to surgical
resection.
14/25 (56%) patients with stents
placed proceeded to surgical
resection.
Adler D. 2009.
USA. [6]
Level III: Follow
up study
Thirteen patients within a single
tertiary referral centre between
April 2006 and November 2007
with oesophageal malignancy and
stricture causing dysphagia. All
were planned to have
neoadjuvant therapy prior to
undergoing planned oesophageal
resection.
Self expanding
silicone-covered
stent. (Polyﬂex)
Technical success of stent
insertion
11/13 (85%) stents inserted
successfully, with 2/13 (15%)
requiring immediate revision; 7/
13 (54%) required dilation of
stricture for insertion.
There is no discussion of objective
markers of changes in nutrition.
Complications Immediate 12/13 (92.3%) experienced chest
discomfort, 1 (7.7%) of whom
required stent removal and
replacement due to severe pain.
Early/Late Stent migration occurred in 6/13
(46%), ﬁve of whom required stent
removal.
2/13 (15%) patients required PEG
feeding for supplemental
nutrition.
Change in dysphagia
score
Mean dysphagia score
signiﬁcantly improved from 3.0/4
to 1.1 (p ¼ 0.005) at 1 week, 0.8
(p ¼ 0.01) at 2 weeks, 0.9
(p ¼ 0.02) at three weeks and 1.0
(p ¼ 0/008) at four weeks follow
up.
Progression to surgery 3/13 (23%) of patients progressed
to surgery.
Siddiqui A. 2009.
USA. [7]
Level III: Follow
up study
Thirty six patients within a single
tertiary referral centre with
oesophageal malignancy and
signiﬁcant dysphagia undergoing
neoadjuvant therapy prior to
planned oesophageal resection.
Self expanding
silicone-covered
stent. (Polyﬂex)
Technical success of stent
insertion
11/12 (92%) stents inserted
successfully, with 2/12 (17%)
requiring predilation. One stent
not inserted due to failure to
traverse stricture, with the patient
subsequently receiving a
jejunostomy tube.
Complications not categorised by
time at which they occurred.
Change in dysphagia
score
(continued on next page)
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Table 1 (continued )
Article & level of
evidence
Patient group assessed Type of stent used Outcomes assessed Summary of ﬁndings Comments
Signiﬁcant improvement from
baseline (3.1) at eight weeks (1.2;
p < 0.005).
Change in body weight Signiﬁcant increase from baseline
(60.5 kg) at eight weeks (65.0 kg;
p < 0.001).
Change in mean serum
albumin
Signiﬁcant increase from baseline
(2.8 g/dL) at eight weeks (3.5 g/dL;
p < 0.001).
Complications 8/11 (73%) patients developed
chest discomfort following the
procedure, all managed with oral
agents.
4/11 (36%) patients developed
stent migration at a mean time of
3.5 weeks; all were
asymptomatic.
Lopes T. 2010.
USA [8]
Level III: Follow
up study
Eleven patients within a single
tertiary referral centre with
oesophageal malignancy causing
dysphagia. All were planned to
have neoadjuvant therapy prior to
undergoing planned oesophageal
resection.
Fully covered self-
expandable metal
stent. (ALIMAXX-
E)
Technical success of stent
insertion
10/11 (90.9%) stents successfully
inserted, nine of whom required
predilation. 1/11 (9.1%) stents
placed too proximally with the
patient subsequently receiving an
NJ tube instead.
Most stents were considered to
have satisﬁed their purpose and
were removed at a mean of 100.4
days (50% removed due to
satisfying their purpose, 10%
because of migration and 10% due
to complications developing). As
such, the authors state that the
improvement in dysphagia score
may be attributable to the success
of neoadjuvant therapy.
Complications Immediate 3/10 (30%) experienced chest
discomfort, relieved by oral
agents.
Delayed 2/10 (20%) experienced stent
migration, one of whom required
stent removal for recurrent
dysphagia. 1/10 (10%) developed
tracheoesophageal ﬁstulation,
requiring stent removal.
Change in dysphagia
score
Dysphagia signiﬁcantly improved
by 3.12/4 at one month (p < 0.05),
sustained at three and six months
follow up.
Stent removal 8/10 (80%) stents removed, 5
(50%) of which were planned and
3 (30%) due to complications.
Removal was universally
described as easy.
Microscopic reaction to
stent
6/8 (75%) stents associated with
ulceration, 6/8 (75%) with
granulation, 4/8 (50%) with polyps
and 1/8 (12.5%) became
embedded.
Progression to surgical
resection
2/10 (20%) patients progressed to
surgery.
Langer F. 2010.
Austria. [9]
Level III: Follow
up study
Thirty eight patients within two
tertiary referral centres, 29 of
whom had oesophageal
malignancy. The remainder had
cardia (8) or subcardial (1) gastric
cancer.
Self expanding
silicone-covered
stent (13)
(Polyﬂex: 13)
Self-expanding
metal stents (25):
Niti-S (1)
Ultraﬂex (7)
Hanaro (5)
Choo (2)
DoStent (1):
Technical success of stent
insertion
37/38 (97.4%) stents inserted
successfully, with 1/38 (2.6%)
leading to perforation and
necessitating acute
oesophagectomy. 12/38 (32%)
required dilation.
Data provided for proportion of
stents of each type which
migrated during the study, with 2/
13 (15.4%) self expanding plastic
stents (Polyﬂex) migrating,
compared with 10/25 (40%) of self
expanding metal stents (6/10
(25%) Niti-S; 2/7 (28.6%) Ultraﬂex;
2/5 (40%) Hanaro; 0/2 Choo; 0/1
DoStent).
Complications Immediate Immediate stent migration in 2/
38 (5.3%) patients; one requiring
stent repositioning and one
requiring stent exchange.
Early/Late Early stent migration in 3/38
(7.9%), two requiring stent
exchange and one requiring
overstenting.
Late stent migration seen in 7/38
(18.4%) patients, causing a
covered perforation requiring
stent removal in one, and
requiring restenting in another
patient.
One stent caused erosion of the
aortic wall at day 61.
Change in dysphagia
score
Dysphagia score signiﬁcantly
improved from 3.0/4.0 to 0.6/4.0
(p < 0.05).
Change in serum albumin
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Table 1 (continued )
Article & level of
evidence
Patient group assessed Type of stent used Outcomes assessed Summary of ﬁndings Comments
Serum albumin did not change in
those who subsequently
underwent surgery (39.9 vs
39.1 mg/dL) but signiﬁcantly fell
in those who did not undergo
surgery, regardless of stenting
(40.0 vs 29.7 mg/dL; p < 0.05).
Progression to surgical
resection
12/38 (31.6%) failed to progress to
surgery; 6 (15.8%) due to disease
progression, 4 (10.5%) due to
reduced performance status, 1
(2.6%) due to pneumonia and 1
(2.6%) due to cisplatin-induced
encephalopathy and sepsis.
Brown R. 2011.
USA [10]
Level III: Follow
up study.
Thirty two patients within two-
institutions between May 2008
and March 2010 with
oesophageal malignancy. (
Self expanding
silicone-covered
stent. (Polyﬂex)
Technical success of
insertion
Successful in 32/32 (100%)
patients; 28/32 (87.5%) requiring
dilatation of the stricture.
No intraoperative complications
were noted to have resulted from
the presence of a stent.
Complications Immediate None
Early 1/32 (3.1%) patient experienced
chest discomfort, managed on
oral agents.
Late Stent migration in 8/32 (25%); two
of whom required intervention
for recurrent dysphagia.
Change in dysphagia
score
Signiﬁcantly decreased from 2.1/4
to 0.6/4 (p < 0.001) within 48 h of
stent placement, with
improvements sustained until
resection.
Change in weight Signiﬁcantly decreased from
84.5 kg to 77.3 kg (p < 0.01)
between pre-stent stage and
resection; 1/32 (3.1%) patient
required jejunostomy insertion
due to signiﬁcant weight loss.
Change in serum albumin Signiﬁcantly decreased from
4.0 mg/dL to 3.6 mg/dL (p ¼ 0.03)
between pre-stent stage and
resection.
Progression to surgical
resection
12/32 (37.5%) did not proceed to
oesophagectomy; 4 (12.5%) due to
poor performance status, 8 (25%)
because of disease progression.
Pellen M. 2012.
UK. [11]
Level III: Follow
up study
Sixteen patients within a single
tertiary-referral centre between
April 2006 and November 2008
with oesophageal malignancy and
stricture causing signiﬁcant
dysphagia.
Self expanding
removable nitinol
braided
polyethylene-
covered alloy
metal stent (SX-
Ella HV)
Technical success of
insertion
Successful in 16/16 (100%). No comment is made on the
proportion of patients requiring
dilatation prior to stent
placement.
Complications Immediate None reported.
Early/Late Distal migration in 43.8% (7/16); 2
(12.5%) of whom required
intervention due to small bowel
obstruction and dysphagia.
Food bolus obstruction in 2/16
(12.5%).
Progression to surgical
resection
6/16 (37.5%) did not progress: 1
(6.25%) due to poor nutrition, 1
(6.25%) at patient's request, 1
(6.25%) due to excellent RT
response, 3 (18.8%) due to disease
progression.
Change in dysphagia
score
Signiﬁcantly decreased from 2.5/4
to 1.1/4 (p ¼ 0.001).
Change in weight No signiﬁcant change: 69.6 kg vs
67.4 kg (p ¼ 0.070)
Change in albumin No signiﬁcant change: 32.8 g/L vs
32.0 g/L (p ¼ 0.440)
Grifﬁths E. 2012.
UK. [12]
Level III: Cohort
study
Twenty two patients within a
single tertiary referral centre
between July 2008 and February
2011 receiving oeophageal stents,
nine of whom had oesophageal
malignancy.
Woven
polydioxanone
biodegradable
stent. (BD SX-
ELLA)
Technical success of
insertion
Successful in 21/22 (96%) of
patients. Placement failed in one
patient due to failure of the stent
to load on to the loading
mechanism.
Technical success rate and change
in dysphagia score are reported
for all indications, rather than
speciﬁcally for the indication
reviewed within this manuscript.
Complications Immediate None reported.
Early Of the 9 patients undergoing
neoadjuvant therapy, 1/9 (11%)
required insertion of a SEMS at 2
(continued on next page)
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Table 1 (continued )
Article & level of
evidence
Patient group assessed Type of stent used Outcomes assessed Summary of ﬁndings Comments
months and 2 (22%) required
supplementary feeding via
jejunostomy and a ﬁne bore NJ
tube within 12 weeks of stenting.
Progression to surgical
resection
6/9 (66%) did not proceed to
surgery; 1 (11%) because of
disease progression, two (22%)
because of failure to gain
sufﬁcient weight and three (33%)
because they became unﬁt for
surgery. The additional 3/9 (33%)
did progress to surgery but were
not resected due to the
recognition of disseminated
disease.
Change in dysphagia
score
Signiﬁcantly improved from 3.0/4
to 2.0/4 (p ¼ 0.0001) at a median
of 47 days.
Krokidis M.
2013. UK. [13]
Level III: Follow
up study
Eleven patients within a single
tertiary-referral centre between
January and December 2011 with
oesophageal malignancy.
Woven
polydioxanone
biodegradable
stent (BD SX-ELLA)
Technical success of
insertion
Successful in 11/11 (100%); 5
(45%) of whom required dilation.
No note is made of whether
patients received CT, RT or CRT.
Mean follow up time was 102
days but it is difﬁcult to determine
the range time times at which
dysphagia scores were estimated.
Complications Immediate None reported.
Early (<30
days)
Precluded oral nutrition in 3/11
(27%): 18% (2) experienced
proximal migration and 9% (1)
developed aspiration pneumonia
secondary to ﬁstulation at level of
bronchial tree.
Late (>30
days)
Stent dysfunction in 5/11 (45%) at
a mean time of 97.8 days; 2 (18%)
died at days 32 and 42 due to
tracheoesophageal ﬁstulation, 3
(27%) required restenting.
Mean stent patency rate 71.5 days (SD 68.3)
Progression to surgical
resection
1/11 (9%) progressed to surgery
despite requiring NJ feeding due
to stent dysfunction.
3/11 (27%) had patent stents and
were awaiting surgery at 52e130
days follow up.
Change in dysphagia
score
Signiﬁcantly decreased from 3 to
1.9 (p ¼ 0.001) in 8/11 (72%) at
study end point.
Martin R. 2014.
USA. [14]
Level III: Follow
up study
Fifty two patients within two
tertiary referral centres with
oesophageal malignancy.
Self expanding
silicone-covered
stent. (Polyﬂex)
Complications 1/52 (1.9%) required feeding
jejunostomy placement due to
poor nutritional intake.
3/52 (5.8%) required stent
replacement following migration.
No note of technical success of
stent insertion or progression to
surgery. The author's closing
claim that ‘consideration of stents
instead of feeding tubes should be
initiated as ﬁrst line in dysphagia
palliation’ is perhaps not
supported without data relating
to progression to surgery.
Change in dysphagia
score
Signiﬁcantly improved from an
average baseline of 66.6 to 1.1
(p < 0.001) at 1 week after
stenting and 11.1 (p < 0.001)
during neoadjuvant therapy.
Change in serum albumin No signiﬁcant change; 4.0 g/dL at
baseline compared with 3.9 g/dL
(p ¼ 0.3) at completion of
neoadjuvant therapy.
Change in performance
status
No signiﬁcant change; Karnofsky
score of 90 at baseline, compared
with 94.4 (p ¼ 0.170) at
completion of neoadjuvant
therapy.
Change in body weight No signiﬁcant change in body
weight; 84.5 kg at baseline
compared with 81.3 kg (p ¼ 0.57)
at completion of neoadjuvant
therapy.
Quality of life measures
relating to eating
restriction (QLQ-C30
score)
Signiﬁcant improvement in
median response to trouble
enjoying meals at one week (4 vs
2; p ¼ 0.004).
Signiﬁcant improvement in
median response to early satiety
from baseline of 4 at one week (2;
p ¼ 0.012) and during
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Table 1 (continued )
Article & level of
evidence
Patient group assessed Type of stent used Outcomes assessed Summary of ﬁndings Comments
neoadjuvant therapy (2;
p ¼ 0.001).
Signiﬁcant improvement in
median response to taking a long
time to complete meals from 4 at
baseline to 3 (p ¼ 0.016) at one
week after stenting.
Signiﬁcant improvement in
median response to difﬁculty
eating from a baseline of 4 to 2 at
1 week (p ¼ 0.015) and 1
(p ¼ 0.002) during neoadjuvant
therapy.
Siddiqui A. 2012.
USA. [15]
Level IV:
Retrospective
case series.
Fifty ﬁve patients within two
tertiary referral centres between
October 2006 and August 2011
with oesophageal malignancy.
Fully covered self-
expandable metal
stents. (ALIMAXX-
E: 22) (WallFlex:
29) (Evolution: 4)
Technical success of
insertion
55/55 (100%) successfully
inserted, none requiring
oesophageal dilatation.
Three different stent types used
but speciﬁc results for each stent
used are not shown, nor is
justiﬁcation for the stent type
utilised. Average weight results
were not available for four
patients.
Complications Immediate 8/55(15%) experienced chest pain,
necessitating stent removal in 2/
55 (3.6%).
Early 1/55 (1.8%) required stent
removal for uncontrollable reﬂux.
1/55 (1.8%) experienced self-
limiting odynophagia.
1/55 (1.8%) required endoscopic
management of food bolus
obstruction.
Late Stent migration occurred in 17/55
(31%) after a mean of 44 days,
with 1/55 (1.8%) requiring stent
replacement for recurrent
dysphagia.
1/55 (1.8%) required oesophageal
repair and oesophagostomy for
perforation sustained whilst
undergoing neoadjuvant therapy.
Progression to surgical
resection
8/55 (15%) underwent attempted
curative resection.
Change in dysphagia
score
Mean dysphagia score
signiﬁcantly improved from a
baseline of 2.4 at 1 week after
stenting (1.0; p < 0.001).
Change in weight There was no signiﬁcant change in
weight at one month after
stenting when compared with
baseline; 149 vs 153 pounds
(p ¼ 0.59).
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to relieve his dysphagia and improve his clinical outcomes.
3. Three-part question
In patients undergoing neo-adjuvant therapy prior to oeso-
phagectomy, does the use of oesophageal stent for the relief of
dysphagia afford improved parameters relating to nutritional sta-
tus, including change in weight and serum albumin, without
negatively impacting on morbidity, progression to surgery and
overall survival?
4. Search strategy
A Medline search limited to the time period of 1st January 1946
to 1st March 2014 was operated using the Ovid interface probed for
the following terms: (oesophagectomy [All Fields] OR oesophageal
neoplasia [All Fields]) AND (neoadjuvant therapy [All Fields] OR
neoadjuvant chemotherapy OR neoadjuvant chemoradiotherapy OR
pre-operative chemotherapy OR pre-operative chemoradiotherapy
OR pre-operative radiotherapy) AND (stent OR nutrition) AND
(outcomes). Results were limited to papers published in the English
language and those relating to Humans. Any manuscript addressingthe use of oesophageal stents during neoadjuvant therapy prior to
oesophagectomy was assessed in detail.5. Search outcome
Two hundred and forty eight papers were found using the
described search strategy, after which abstracts were independently
reviewed by both authors and those which were not deemed rele-
vant were excluded from further analysis. Of the 248 abstracts
initially identiﬁed, twelvemanuscriptswere identiﬁed that provided
the best evidence to answer the clinical question. A total of 237
manuscripts were excluded from further analysis; 35 of which did
not relate to the use of stents, 53 which were not directly applicable
to oesophageal pathology and/or oesophageal malignancy, 115 of
which related to the post-operative use of stents and the remainder
of which constituted review articles or isolated case reports.6. Discussion
Eleven level III follow up studies and one level IV retrospective
case series were identiﬁed to be relevant to the research question,
as illustrated within Tables 1 and 2 [4e15].
Table 2
Summary of key ﬁndings, by stent type and year of publication.
No. of
patients
Neo-adj
therapya
Stent
type
studied
Insertion Signiﬁcant
improvement in
dysphagia?
Change in mean
serum albumin
Change
in weight
Complications (%) % Requiring
supplementary tube
feeding
% Requiring unplanned
stent removal/replacement
% Progression to
surgical resectionb
%
Success
%
Requiring
dilation
Chest
discomfort
Stent
migration
Erosion or
ﬁstulation
Christie
A;
2001
100 CT/CRT SEMS NR NR Y NR NR 0 0 12 12 12 NR
Bower
M;
2009
25 CRT SEPS 100 56 Y [ 4 0 20 0 8 20 56
Adler D;
2009
13 CRT SEPS 85 54 Y NR NR 92.3 46 0 15 15 23
Siddiqui
A;
2009
36 CRT SEPS 92 17 Y [ [ 73 36 0 0 0 NR
Lopes T;
2010
11 CRT SEMS 91 82 Y NR NR 30 20 10 0 30 20
Langer F;
2010
38 CT/CRT SEP/MS 97 32 Y Y NR NR 32 9 3 29 52.6
Brown R;
2011
32 CT/CRT SEPS 100 87.5 Y Y Y 3.1 25 0 3.1 0 62.5
Pellen M;
2012
16 CT SEMS 100 NR Y 4 4 0 44 0 0 0 62.5
Grifﬁths
E;
2012
22 CT SEBS 96 NR Y NR NR 0 NR NR 22 66 0
Krokidis
M;
2013
11 CT/CRT SEBS 100 45 Y NR NR 0 18 18 9 27 0e27
Martin R;
2014
52 CT/CRT SEPS NR NR Y NR NR NR 6 NR 1.9 5.8 NR
Siddiqui
A;
2012
55 CRT SEMS 100 0 Y NR 4 15 31 1.8 0 3.6 15
Key: NR e Not recorded/measured, YeYes, NeNo,4eNo change (stable), [eSigniﬁcant increase seen, YeSigniﬁcant decrease seen, SEBSeSelf expanding biodegradable stent, SEMSeSelf expanding metal stent.
a CTeChemotherapy; CRTeChemoradiotherapy.
b Without requiring additional nutritional supplementation via nasojejunal or feeding jejunostomy tube. Results are shown as a percentage of those who had stents successfully inserted.
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of stent insertion, rates of which vary between 85 and 100%
[6e13,15]. Failures are attributed within the studied series to an
inability to traverse strictures, proximal stent placement, failure of
the stent loading mechanism and one perforation which necessi-
tated acute oesophagectomy [7e9,12]. Eight manuscripts reported
the use of pre-dilatation prior to stent placement, rates of which
varied between 17 and 85.5% [5e10,13,14]. Adler et al. additionally
note that two of the thirteen patients included within their series
required immediate revision of stent placement [6].
Placement of an oesophageal stent signiﬁcantly improved
overall dysphagia scores in all twelve studies reviewed [4e15]. This
improvement is noted to occur within 48 h of stent placement and
is reported to continue for the duration of follow up in three studies
respectively extending to four, eight and 24 weeks, and to time of
resection in a further two studies [4e15]. Supplementary feeding
tube placement was nevertheless required due to recurrent
dysphagia by two of 100 patients reported by Christie et al., by two
of 25 patients reported by Bower et al. and by one of 11 patients
identiﬁed by Krokidis et al. [4,5,13].
As is summarised within Table 2, there was no consistent
improvement seen in markers of nutritional status, with mixed
reports of both weight and serum albumin levels increasing,
decreasing or remaining unchanged following stent insertion
[5,7,9e11,15].
Rates of progression to surgical resection vary signiﬁcantly be-
tween manuscripts from a nadir of 0%, reported with the use of
biodegradable stents by Grifﬁths et al., to a peak of 56%
[5,6,8e13,15]. Noting that 33% of patients with biodegradable
stents inserted within their 2012 study progressed to theatre but
were deemed unsuitable for intervention at the time of attempted
resection, Grifﬁths et al. additionally highlight that 66% were
deemed unﬁt for surgery pre-operatively, two thirds of whom had
failed to gain sufﬁcient weight [12]. Pellen et al. provide further
analysis of poor rates of progression to surgical resection, noting
that just one of the six patients within their sixteen strong cohort
who failed to progress to surgery did so as a result of poor nutri-
tional status, with three experiencing signiﬁcant disease progres-
sion [11]. These ﬁndings are supported by Brown et al. who identify
that whilst two thirds of their patients who failed to progress to
resection did so because of disease progression, one third had
experienced a signiﬁcant decline in their performance status [10].
Whilst Langer et al. report cisplatin-induced encephalopathy and
pneumonia as prohibiting resection in twelve of their patients who
failed to progress to surgery, they too additionally identify disease
progression and reduced performance status as principal factors
underlying failed surgical resection [9].
There are numerous reports of complications arising within the
studied series. Christie et al. identify two patients who developed
signiﬁcant complications, including one death from sepsis sec-
ondary to the development of a mediastinal abscess following stent
erosion [4]. A further patient required neurosurgical drainage after
stent erosion into the T1 vertebral body caused an abscess [4].
Bower et al. make note of six (24%) patients who experienced stent
migration, all of whom had responded to neoadjuvant therapy [5].
One patient additionally experienced chest discomfort signiﬁcant
enough towarrant readmission [5]. This immediate complication of
stent placement is reiterated by Siddiqui's 2007 series, which re-
ported that 73% of patients were affected by chest pain, and Adler's
2009 prospective level III study of thirteen patients undergoing
SEPS placement [6,7]. Within this population, 92.3% (12) patients
experienced chest discomfort which was severe enough in 7.7% (1)
to warrant stent removal and replacement [6]. Stent migration is
again recognised as a complication, affecting six (46%) patients, ﬁve
of whom required removal of their stent [6].Thirty percent of patients within Lopes' analysis experienced
chest discomfort and an additional 30% (3) required stent removal
for complications [8]. Two of these patients had experienced stent
migration whereas one developed tracheoesophageal ﬁstulation
[8]. Serious stent related complications were additionally reported
by Langer et al., including perforation (n ¼ 1), mediastinitis (n ¼ 1),
tracheoesophageal ﬁstulation (n ¼ 2), bleeding (n ¼ 1) and jejunal
perforation (n ¼ 1) [9]. Of clinical relevance, 18.5% of the patients in
this study required endoscopic intervention (either stent replace-
ment or repositioning) due to stent migration [9].
Despite successful initial stent placement in 11/11 patients
studied by Krokidis et al., early complications occurred in 3/11
(27.2%), none of whomwere subsequently able to be fed orally [13].
One patient experienced proximal stent migration within two days
of its deployment, leading to vocal cord dysfunction and tracheo-
bronchial aspiration secondary to a tracheoesophageal ﬁstula [13].
A second patient experienced proximal stent migration, again
within the ﬁrst 48 h of placement, presenting as aspiration and
haematemesis [13]. The third developed pneumonia secondary to a
ﬁstula to the bronchial treewhich developed after threeweeks [13].
Importantly, two of the eight patients with sustained stent place-
ment died due to the development of tracheosophageal ﬁstulae at
days 42 and 62 [13].
Finally, Siddiqui et al. identiﬁed pain as a signiﬁcant conse-
quence of stent placements within their 2012 series of 55 patients,
with two of the 13 patients requiring stent removal due to the
severity of their discomfort [15]. Further, stent migration occurred
in 17 (31%) patients, with a further patient undergoing a delayed
perforation [15]. In spite of this, Brown et al. report just 3.1% (1) of
the patients within their analysis experiencing chest discomfort,
though eight (25%) experienced stent migration, albeit with only
two requiring endoscopic intervention [10].
7. Clinical bottom line
Stent placement is effective for relieving dysphagia in patients
undergoing neo-adjuvant chemotherapy but does not consistently
translate to maintenance or improvement in either weight or
serum albumin levels. Stents placed for this indication additionally
consistently require reintervention due either to migration or chest
pain and are associated with both signiﬁcant variation in the rate of
patients progressing to curative surgery and uncommon life
threatening complications including oesophageal perforation,
medinastinitis, aortic erosion and tracheo-oesophageal ﬁstulation.
The use of stents in this scenario cannot be supported.
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